Loading clinical trials...
Loading clinical trials...
Phase I Trial of Post Transplant Immunization With Autologous Myeloma Idiotype-KLH/GM-CSF In Myeloma Patients Following Autologous or Allogeneic Marrow or Stem Cell Transplantation
Conditions
Interventions
autologous immunoglobulin idiotype-KLH conjugate vaccine
sargramostim
+2 more
Locations
1
United States
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
Start Date
March 1, 1996
Primary Completion Date
December 1, 2002
Last Updated
May 6, 2019
NCT04973605
NCT06138275
NCT05862012
NCT07284758
NCT06285318
NCT07391657
Lead Sponsor
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions